Abstract: Objective　To investigate the application and clinical significance of combined determination of cardiac troponin I（cTnI），ischemia modified albumin（IMA） and high sensitive C reactive protein（hs-CRP） in coronary heart disease.   Methods　Enzyme-linked immunosorbent assay (ELISA) kits from the same company were used to measure the all markers. According to the measured results of cTnI were higher or not than the reference value (0.173ng/mL), 142 patients were classified into 2 groups ［cTnI non-increasing (<0.173 ng/mL) group: 91 cases, cTnI increasing (≥0.173 ng/mL) group: 51 cases］. A total of 78 healthy subjects were enrolled as controls. The combined determination of cTnI, IMA and hs-CRP was performed. Results　Among coronary heart disease patients in cTnI non-increasing group, their IMA and hs-CRP levels increased slightly compared with those in the control group（P<0.05）. The IMA and hs-CRP levels among coronary heart disease patients in cTnI increasing group increased significantly（P<0.01）. Among coronary heart disease paritents in cTnI non-increasing group, the IMA levels of 27 patients (30%) increased slightly, and the hs-CRP levels of 34 patients (37%) increased. Conclusions　The combined determination of cTnI，IMA and hs-CRP has complementation significance in diagnosis of myocardial ischemia and myocardial injury.

Key words: Cardiac troponin I, Ischemia modified albumin, High sensitive C reactive protein, Coronary heart disease